# Top 30 ranked extracts from Θεραπευτικά_Πρωτόκολλα_ΕΟΠΕ-10η_Έκδοση_cleaned.json.cleaned_population.txt

=== Ranked Extract 1 (#7, Patients) — Score: 9 ===
2;11:193, x.
33.Kudo M, Finn RS, Qin S et al; Lenvatinib versus sorafenib in first-line treatment of patients with
unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar
34.Bruix J, Qin S, Merle P, Granito A et al ; RESORCE Investigators. Regorafenib for patients with
hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-
blind, placebo-controlled, phase 3 trial. Lancet. 2017 Jan 7;389(10064):56-66. Epub 2016 Dec 6
35.Abou-Alfa GK, Meyer T, Cheng AL et al ; Cabozantinib in patients with advanced and progressing
hepat

=== Ranked Extract 2 (#8, Patients) — Score: 9 ===
ORCE Investigators. Regorafenib for patients with
hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-
blind, placebo-controlled, phase 3 trial. Lancet. 2017 Jan 7;389(10064):56-66. Epub 2016 Dec 6
35.Abou-Alfa GK, Meyer T, Cheng AL et al ; Cabozantinib in patients with advanced and progressing
hepatocellular carcinoma. N Engl J Med. 2018 Jul 5;379(1):54-63
36.Zhu AX, Kang YK, Yen CJ ae al , ; REACH-2 study investigators. Ramucirumab after sorafenib in patients
with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a
rand

=== Ranked Extract 3 (#9, Patients) — Score: 9 ===
Jan 7;389(10064):56-66. Epub 2016 Dec 6
35.Abou-Alfa GK, Meyer T, Cheng AL et al ; Cabozantinib in patients with advanced and progressing
hepatocellular carcinoma. N Engl J Med. 2018 Jul 5;379(1):54-63
36.Zhu AX, Kang YK, Yen CJ ae al , ; REACH-2 study investigators. Ramucirumab after sorafenib in patients
with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a
randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Feb;20(2):282-296.
37.El-Khoueiry AB, Sangro B, Yau T et al; Nivolumab in patients with advanced hepatocellular carcinoma
(C

=== Ranked Extract 4 (#10, Patients) — Score: 9 ===
stigators. Ramucirumab after sorafenib in patients
with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a
randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Feb;20(2):282-296.
37.El-Khoueiry AB, Sangro B, Yau T et al; Nivolumab in patients with advanced hepatocellular carcinoma
(CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet.
2017 Jun 24;389(10088):2492-2502.
38.Zhu AX, Finn RS, Edeline J et al; KEYNOTE-224 investigators. Pembrolizumab in patients with advanced
hepatocellular car

=== Ranked Extract 5 (#18, Patients) — Score: 9 ===
th cancer, especially that attributable to cancer
treatment. Health Technol Assess 2007;11:1-202.
5. Ludwig H, Van Belle S, Barrett-Lee, et al The European Cancer Anaemia Survey (ECAS): a large,
multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in
cancer patients. Eur J Cancer 2004;40:2293-2306.
6. Jabbour E, Kantarjian HM, Koller C, Taher A Red blood cell transfusions and iron overload in the
treatment of patients with myelodysplastic syndromes. Cancer 2008;112:1089-1095.
7. Birgegård G, Gascón P, Ludwig H. Evaluation of anaemia in patients with multiple m

=== Ranked Extract 6 (#19, Patients) — Score: 9 ===
Cancer Anaemia Survey (ECAS): a large,
multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in
cancer patients. Eur J Cancer 2004;40:2293-2306.
6. Jabbour E, Kantarjian HM, Koller C, Taher A Red blood cell transfusions and iron overload in the
treatment of patients with myelodysplastic syndromes. Cancer 2008;112:1089-1095.
7. Birgegård G, Gascón P, Ludwig H. Evaluation of anaemia in patients with multiple myeloma and
lymphoma: findings of the European Cander Anaemia Survey. Eur J Haematol 2006;77:378-386.
8.  (last accessed 8 May 2009).
9. Harper P, Littlewoo

=== Ranked Extract 7 (#20, Patients) — Score: 9 ===
aemia in
cancer patients. Eur J Cancer 2004;40:2293-2306.
6. Jabbour E, Kantarjian HM, Koller C, Taher A Red blood cell transfusions and iron overload in the
treatment of patients with myelodysplastic syndromes. Cancer 2008;112:1089-1095.
7. Birgegård G, Gascón P, Ludwig H. Evaluation of anaemia in patients with multiple myeloma and
lymphoma: findings of the European Cander Anaemia Survey. Eur J Haematol 2006;77:378-386.
8.  (last accessed 8 May 2009).
9. Harper P, Littlewood T. Anaemia of cancer: impact on patient fatigue and long-term outcome.
Oncology 2005;69 Suppl 2:2-7.
αρχική εκτίμηση και η περι

=== Ranked Extract 8 (#27, Patients) — Score: 9 ===
10. Nicolatou-Galitis O, Papadopoulou E, Vardas E, et al (2020) Alveolar bone histological necrosis observed
prior to extractions in patients, who receive bone-targeting agents. Oral Dis 26: 955-966.
11. Ristow O, et al (2021a). Wound closure and alveoloplasty after preventive tooth extractions in patients
with antiresorptive intake-A randomized pilot study. Oral Diseases 27:532-546.
12. Ristow O, et al (2021b). Diagnostic accuracy comparing OPG and CBCT in the detection of non-vital bone
changes before tooth extractions in patients with antiresorptive intake. Oral Diseases, 2021:00:1-11, 7
October 2

=== Ranked Extract 9 (#28, Patients) — Score: 9 ===
ound closure and alveoloplasty after preventive tooth extractions in patients
with antiresorptive intake-A randomized pilot study. Oral Diseases 27:532-546.
12. Ristow O, et al (2021b). Diagnostic accuracy comparing OPG and CBCT in the detection of non-vital bone
changes before tooth extractions in patients with antiresorptive intake. Oral Diseases, 2021:00:1-11, 7
October 2021.
13. Otto S, Pautke C, Van den Wyngaert T, et al (2018). Medication-related osteonecrosis of the jaw:
Prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treatment
Reviews 69:177-187.
14. Fu

=== Ranked Extract 10 (#39, Patients) — Score: 9 ===
a H, et al. Docetaxel and cisplatin in first line treatment of patients with
Row 18: nown primary cancer: a multicenter study of the anatolian society of medical oncology. Asian Pac J
Row 19: cer Prev. 2014;15(4):1581–1584.
Row 20: emori K, Ando M, Yunokawa M, et al. Irinotecan plus carboplatin for patients with carcinoma of Row 1: 
Row 2: 42. Hainsworth JD, Spigel DR, Clark BL, et al. Paclitaxel/carboplatin/etoposide versus
Row 3: gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a Row 1: review of 56 cases. Cancer 1987; 59:572.
Row 2: 44. Mukai H,

=== Ranked Extract 11 (#40, Patients) — Score: 9 ===
: cer Prev. 2014;15(4):1581–1584.
Row 20: emori K, Ando M, Yunokawa M, et al. Irinotecan plus carboplatin for patients with carcinoma of Row 1: 
Row 2: 42. Hainsworth JD, Spigel DR, Clark BL, et al. Paclitaxel/carboplatin/etoposide versus
Row 3: gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a Row 1: review of 56 cases. Cancer 1987; 59:572.
Row 2: 44. Mukai H, Katsumata N, Ando M, et al. Safety and efficacy of a combination of docetaxel and cisplatin in
Row 3: patients with unknown primary cancer. Am J Clin Oncol. 2010;33:32–35.
Row 4: 45. Pointr

=== Ranked Extract 12 (#49, Patients) — Score: 9 ===
):1789.
Row 3: 4. Massie MJ, Holland J, Glass E. Delirium in terminally ill cancer patients. Am J Psychiatry 1983; 140:1048.
Row 4: 5. Breitbart W, Marotta R, Platt MM, et al. A double-blind trial of haloperidol, chlorpromazine, and
Row 5: lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 1996; 153:231.
Row 6: 6. Hui D, Frisbee-Hume S, Wilson A, et al. Effect of Lorazepam With Haloperidol vs Haloperidol Alone on
Row 7: Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical
Row 8: Trial. JAMA 2017; 318:1047.
Row 9: 7. Boet

=== Ranked Extract 13 (#6, Patients) — Score: 8 ===
V, Sorafenib in advanced hepatocellular carcinoma N Engl J Med. 2008 Jul
2. Martin RC, Jarnagin WR. Randomized clinical trials in hepatocellular carcinoma and biliary cancer. Surg
Oncol Clin N Am 2002;11:193, x.
33.Kudo M, Finn RS, Qin S et al; Lenvatinib versus sorafenib in first-line treatment of patients with
unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar
34.Bruix J, Qin S, Merle P, Granito A et al ; RESORCE Investigators. Regorafenib for patients with
hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-

=== Ranked Extract 14 (#11, Patients) — Score: 8 ===
gro B, Yau T et al; Nivolumab in patients with advanced hepatocellular carcinoma
(CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet.
2017 Jun 24;389(10088):2492-2502.
38.Zhu AX, Finn RS, Edeline J et al; KEYNOTE-224 investigators. Pembrolizumab in patients with advanced
hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-
label phase 2 trial. Lancet Oncol. 2018 Jul;19(7):940-952
39.Qin S., Bai Y., Lim HY., Randomized, multicentre, open label study of oxaliplatin plus 5FU/leucovorin
versus doxorubicin as pa

=== Ranked Extract 15 (#15, Patients) — Score: 8 ===
08. doi: 10.1007/s40257-
016-0207-3 [published Online First: 2016/07/01]
18. AssociazioneItaliana di Oncologia Medica (AIOM). LineeGuidaAIOM 2018 TUMORICUTANEINON
MELANOMA-Carcinoma squamocellularecutaneo, 2018.
21. Primary analysis of Phase 2 results of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with
locally advanced cutaneous squamous cell carcinoma (laCSCC). ASCO Annual Meeting; 2019
22. Migden MR, Khushalani N, Chang A. Primary Analysis of Phase 2 results of Cemiplimab, a human
monoclonal anti-PD-1, in patients with locally advanced cutaneous squamous cell carcinoma 2019
American

=== Ranked Extract 16 (#16, Patients) — Score: 8 ===
sis of Phase 2 results of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with
locally advanced cutaneous squamous cell carcinoma (laCSCC). ASCO Annual Meeting; 2019
22. Migden MR, Khushalani N, Chang A. Primary Analysis of Phase 2 results of Cemiplimab, a human
monoclonal anti-PD-1, in patients with locally advanced cutaneous squamous cell carcinoma 2019
American Society of Clinical Oncology Annual Meeting. Chicago, Illinois, 2019.
Το βασικοκυτταρικό καρκίνωμα (basalcellcarcinoma, BCC) αντιπροσωπεύει περίπου το 80% όλων των μη
μελανοκυτταρικών καρκίνων του δέρματος [1]. Τα BCCs γενικά ανα

=== Ranked Extract 17 (#29, Patients) — Score: 8 ===
CBCT in the detection of non-vital bone
changes before tooth extractions in patients with antiresorptive intake. Oral Diseases, 2021:00:1-11, 7
October 2021.
13. Otto S, Pautke C, Van den Wyngaert T, et al (2018). Medication-related osteonecrosis of the jaw:
Prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treatment
Reviews 69:177-187.
14. Fusco V, Santini D, Campisi G, et al (2020). Comment on Medication-Related Osteonecrosis of the Jaw:
MASCC/ISOO/ASCO Clinical Practice Guideline Summary. JCO Oncol Pract 16:142-145, doi:
10.1200/JOP.19.00645.
15. Ristow O, Rü

=== Ranked Extract 18 (#31, Patients) — Score: 8 ===
oto Y, Kaneishi K, Odagiri T, Sakurai H, Katayama H,
Mori I, Yamada H, Watanabe H, Yokoyama T, Yamaguchi T, Nishi T, Shirado A, Hiramoto S, Watanabe T,
Kohara H, Shimoyama S, Aruga E, Baba M, Sumita K, Iwase S. Predictors of Responses to Corticosteroids
for Cancer-Related Fatigue in Advanced Cancer Patients: A Multicenter, Prospective, Observational Study.
J Pain Symptom Manage. 2016;52(1):64
0.5 – 1mg. Η χορήγησης μπορεί να επαναληφθεί σε διάστημα 45 – 60 λεπτών (4).
1. Kang JH, Shin SH, Bruera E. Comprehensive approaches to managing delirium in patients with advanced
cancer. Cancer Treat Rev 2013; 3

=== Ranked Extract 19 (#32, Patients) — Score: 8 ===
for Cancer-Related Fatigue in Advanced Cancer Patients: A Multicenter, Prospective, Observational Study.
J Pain Symptom Manage. 2016;52(1):64
0.5 – 1mg. Η χορήγησης μπορεί να επαναληφθεί σε διάστημα 45 – 60 λεπτών (4).
1. Kang JH, Shin SH, Bruera E. Comprehensive approaches to managing delirium in patients with advanced
cancer. Cancer Treat Rev 2013; 39: 105–112
2. Scottish Partnership for Palliative Care. Scottish Palliative Care Guidelines – Delirium. Scotland: NHS
Scotland, Healthcare Improvement Scotland 2014
3. Lipowski ZJ Delirium (acute confusional states).JAMA. 1987;258(13):1789.
4. Massie MJ

=== Ranked Extract 20 (#35, Patients) — Score: 8 ===
w 15: 39. Cheeseman SL, Joel SP, Chester JD, et al. A ‘modified de Gramont’ regimen of fluorouracil, alone and with
Row 16: oxaliplatin, for advanced colorectal cancer. Br J Cancer. 2002;87:393–399.
Row 17: 40. Demirci U, Coskun U, Karaca H, et al. Docetaxel and cisplatin in first line treatment of patients with
Row 18: unknown primary cancer: a multicenter study of the anatolian society of medical oncology. Asian Pac J
Row 19: Cancer Prev. 2014;15(4):1581–1584.
Row 20: 41. Yonemori K, Ando M, Yunokawa M, et al. Irinotecan plus carboplatin for patients with carcinoma of Row 1: Harb
Row 2: 33. Bria
Row

=== Ranked Extract 21 (#36, Patients) — Score: 8 ===
ocetaxel and cisplatin in first line treatment of patients with
Row 18: unknown primary cancer: a multicenter study of the anatolian society of medical oncology. Asian Pac J
Row 19: Cancer Prev. 2014;15(4):1581–1584.
Row 20: 41. Yonemori K, Ando M, Yunokawa M, et al. Irinotecan plus carboplatin for patients with carcinoma of Row 1: Harb
Row 2: 33. Bria
Row 3: A ph
Row 4: 34. Grec
Row 5: treat
Row 6: 35. Grec
Row 7: plus
Row 8: 36. Gros
Row 9: unkn
Row 10: 37. Poue
Row 11: carc
Row 12: 38. Cass
Row 13: com
Row 14: canc
Row 15: 39. Chee
Row 16: oxali
Row 17: 40. Dem
Row 18: unkn
Row 19: Canc
Row 20: 41.

=== Ranked Extract 22 (#38, Patients) — Score: 8 ===
;26:2006–2012.
Row 15: eseman SL, Joel SP, Chester JD, et al. A ‘modified de Gramont’ regimen of fluorouracil, alone and with
Row 16: iplatin, for advanced colorectal cancer. Br J Cancer. 2002;87:393–399.
Row 17: mirci U, Coskun U, Karaca H, et al. Docetaxel and cisplatin in first line treatment of patients with
Row 18: nown primary cancer: a multicenter study of the anatolian society of medical oncology. Asian Pac J
Row 19: cer Prev. 2014;15(4):1581–1584.
Row 20: emori K, Ando M, Yunokawa M, et al. Irinotecan plus carboplatin for patients with carcinoma of Row 1: 
Row 2: 42. Hainsworth JD, Spigel DR,

=== Ranked Extract 23 (#41, Patients) — Score: 8 ===
/etoposide versus
Row 3: gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a Row 1: review of 56 cases. Cancer 1987; 59:572.
Row 2: 44. Mukai H, Katsumata N, Ando M, et al. Safety and efficacy of a combination of docetaxel and cisplatin in
Row 3: patients with unknown primary cancer. Am J Clin Oncol. 2010;33:32–35.
Row 4: 45. Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-
Row 5: fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst. 2009;101:498–506.
Row 6: 46. Ku

=== Ranked Extract 24 (#42, Patients) — Score: 8 ===
Randomized trial of induction chemotherapy with cisplatin and 5-
Row 5: fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst. 2009;101:498–506.
Row 6: 46. Kusaba H, Shibata Y, Arita S, et al. Infusional 5-fluorouracil and cisplatin as first-line chemotherapy in
Row 7: patients with carcinoma of unknown primary site. Med Oncol. 2007;24:259–264.
Row 8: 47. Park YH, Ryoo BY, Choi SJ, et al. A phase II study of paclitaxel plus cisplatin chemotherapy in an
Row 9: unfavourable group of patients with cancer of unknown primary site. Jpn J Clin Oncol. 2004;34:681–685.
Row 10: 48.

=== Ranked Extract 25 (#43, Patients) — Score: 8 ===
et al. Infusional 5-fluorouracil and cisplatin as first-line chemotherapy in
Row 7: patients with carcinoma of unknown primary site. Med Oncol. 2007;24:259–264.
Row 8: 47. Park YH, Ryoo BY, Choi SJ, et al. A phase II study of paclitaxel plus cisplatin chemotherapy in an
Row 9: unfavourable group of patients with cancer of unknown primary site. Jpn J Clin Oncol. 2004;34:681–685.
Row 10: 48. Pantheroudakis G, Briasoulis E, Kalofonos HP, et al. Docetaxel and carboplatin combination
Row 11: chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicenter Hellenic
Row 12: Cooper

=== Ranked Extract 26 (#50, Patients) — Score: 8 ===
uble-blind trial of haloperidol, chlorpromazine, and
Row 5: lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 1996; 153:231.
Row 6: 6. Hui D, Frisbee-Hume S, Wilson A, et al. Effect of Lorazepam With Haloperidol vs Haloperidol Alone on
Row 7: Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical
Row 8: Trial. JAMA 2017; 318:1047.
Row 9: 7. Boettger S, Jenewein J, Breitbart W. Haloperidol, risperidone, olanzapine and aripiprazole in the
Row 10: management of delirium: A comparison of efficacy, safety, and side effects. Pa

=== Ranked Extract 27 (#3, Patients) — Score: 7 ===
ated analysis of three phase 1-2 trials. Lancet Oncol. 2020 Feb;21(2):271-282. doi:
10.1016/S1470-2045(19)30691-6,PMID: 31838007; PMCID: PMC7461630.
110. Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried
M, Diaz LA Jr et al, Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite
Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin
Oncol. 2020 Jan 1;38(1):1-10. doi: 10.1200/JCO.19.02105. PMID: 31682550; PMCID: PMC8184060.
111. Subbiah V, Wolf J, Konda B, Kang H, Spira A, Weiss J, Takeda M, O

=== Ranked Extract 28 (#4, Patients) — Score: 7 ===
col. 2020 Jan 1;38(1):1-10. doi: 10.1200/JCO.19.02105. PMID: 31682550; PMCID: PMC8184060.
111. Subbiah V, Wolf J, Konda B, Kang H, Spira A, Weiss J, Takeda M, Ohe Y, Khan S, Ohashi K,
Soldatenkova V, Szymczak S, Sullivan L, Wright J, Drilon A. Tumour-agnostic efficacy and safety of
selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours
(LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol. 2022 Oct;23(10):1261-1273. doi: a)
Στάδια IA και ΙΒ σε όγκους χαμηλής διαφοροποίησης (grade 3)
b)
Στάδια ΙC-IV
ΘΕΡΑΠΕΙΑ ΣΥΝΤΗΡΗΣΗΣ (MAINTENANCE) Paclitaxel

=== Ranked Extract 29 (#5, Patients) — Score: 7 ===
gestrolacetate
iii. Medroxyprogesteroneacetate
iv. GnRHanalogs
Meri
expre
Onco
ic-Bernstam F, Ma
essing solid tumo
ology Annual Mee
akker V, Oaknin A, et al. Efficacy and safety of trastuzu
ors: DESTINYPanTumor02 interim results. Presente
eting; June 2–6, 2023; Chicago, Illinois.
umab deruxtecan in patients with HER2-
ed at the American Society of Clinical του ανθρώπινου θηλώματος (HPV). Ο εμβολιασμός, έναντι υποτύπων του ιού HPV, δεν αναιρεί τις ισχύουσες
Το θεραπευτικό πλάνο που ακολουθείται σε ασθενείς πρώιμου σταδίου κατά FIGO (IA, IB1 και ΙΙΑ ≤4 cm) [3]
i. είτε ριζική υστερεκτομή (με ή χωρίς adju

=== Ranked Extract 30 (#12, Patients) — Score: 7 ===
ular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-
label phase 2 trial. Lancet Oncol. 2018 Jul;19(7):940-952
39.Qin S., Bai Y., Lim HY., Randomized, multicentre, open label study of oxaliplatin plus 5FU/leucovorin
versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma form
Asia, J. Clin. Oncol.2013;31:3501-3508
Διπλασιασμός των ανάλογων σωματοστατίνης ή συνδυασμός με τελοτριστάτη (TELECAST study) ή συνδυασμός
με ιντερφερόνη-α (5 x 10 U sc).
PRRT ή τοπική θεραπεία ηπατικών μεταστάσεων
( χημειοθεραπεία ή everolimus εκτός ένδε

